Kindred Biosciences, Inc. (KIN) in Focus: Stock Soars 10.6% – Tale of the Tape

Zacks

Kindred Biosciences, Inc. (KIN) was a big mover last session, as the company saw its shares rise by nearly 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent trend for the company as the stock is now down 31.96% since Nov 24, 2014.

The company has seen three positive revisions in the past one month, while its Zacks Consensus Estimate moved higher over the same time frame, suggesting that more solid trading could be ahead for this stock. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Kindred Biosciences currently carries a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Other well-placed stocks in the same industry include Affymetrix Inc. (AFFX), ANI Pharmaceuticals, Inc. (ANIP) and Biogen Idec Inc. (BIIB). All these stocks carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

Be the first to comment

Leave a Reply